Hyundai Pharmaceutical Statistics

Total Valuation

Hyundai Pharmaceutical has a market cap or net worth of KRW 97.01 billion.

Market Cap	97.01B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Hyundai Pharmaceutical has 27.68 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	27.68M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	26.39%
Owned by Institutions (%)	0.68%
Float	19.87M

Valuation Ratios

The trailing PE ratio is 58.09.

PE Ratio	58.09
Forward PE	n/a
PS Ratio	0.76
PB Ratio	0.82
P/TBV Ratio	n/a
P/FCF Ratio	16.99
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.20, with a Debt / Equity ratio of 0.21.

Current Ratio	2.20
Quick Ratio	1.62
Debt / Equity	0.21
Debt / EBITDA	4.83
Debt / FCF	3.63
Interest Coverage	2.25

Financial Efficiency

Return on equity (ROE) is 1.45% and return on invested capital (ROIC) is 1.09%.

Return on Equity (ROE)	1.45%
Return on Assets (ROA)	0.93%
Return on Capital (ROIC)	1.09%
Revenue Per Employee	275.15M
Profits Per Employee	3.60M
Employee Count	393
Asset Turnover	0.74
Inventory Turnover	3.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.20% in the last 52 weeks. The beta is 0.54, so Hyundai Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	-11.20%
50-Day Moving Average	4,238.60
200-Day Moving Average	4,058.90
Relative Strength Index (RSI)	30.13
Average Volume (20 Days)	780,495

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hyundai Pharmaceutical had revenue of KRW 108.14 billion and earned 1.41 billion in profits. Earnings per share was 60.34.

Revenue	108.14B
Gross Profit	40.49B
Operating Income	2.19B
Pretax Income	1.15B
Net Income	1.41B
EBITDA	4.30B
EBIT	2.19B
Earnings Per Share (EPS)	60.34

Full Income Statement

Balance Sheet

The company has 14.63 billion in cash and 20.75 billion in debt, giving a net cash position of -6.12 billion or -221.10 per share.

Cash & Cash Equivalents	14.63B
Total Debt	20.75B
Net Cash	-6.12B
Net Cash Per Share	-221.10
Equity (Book Value)	101.21B
Book Value Per Share	4,294.60
Working Capital	43.83B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.95 billion and capital expenditures -2.24 billion, giving a free cash flow of 5.71 billion.

Operating Cash Flow	7.95B
Capital Expenditures	-2.24B
Free Cash Flow	5.71B
FCF Per Share	206.29

Full Cash Flow Statement

Margins

Gross margin is 37.44%, with operating and profit margins of 2.02% and 1.31%.

Gross Margin	37.44%
Operating Margin	2.02%
Pretax Margin	1.06%
Profit Margin	1.31%
EBITDA Margin	3.97%
EBIT Margin	2.02%
FCF Margin	5.28%

Dividends & Yields

This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 1.01%.

Dividend Per Share	35.00
Dividend Yield	1.01%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	62.32%
Buyback Yield	-0.09%
Shareholder Yield	0.93%
Earnings Yield	1.72%
FCF Yield	5.89%

Dividend Details

Stock Splits

The last stock split was on March 13, 2008. It was a forward split with a ratio of 10.

Last Split Date	Mar 13, 2008
Split Type	Forward
Split Ratio	10

Scores

Hyundai Pharmaceutical has an Altman Z-Score of 2.5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.5
Piotroski F-Score	n/a